title: [Nasal cavity and paranasal sinus cancer].
abstract: The nasal cavity and parasinusal cancer are rare (10% of tumors of the head and neck) and are mainly represented by squamous cell carcinoma of the nasal cavity or the maxillary sinus and adenocarcinoma of the ethmoid sinus (occupational disease, wood dust). The most common clinical sign is nasal obstruction, but tumors can also manifest as rhinorrhea and/or epistaxis (usually unilateral signs). A magnetic resonance imaging of the facial structure is systematic for staging before treatment. The treatment consists of a first surgery if the patient is operable with a resectable tumor. If it is not the case, the treatment consists of radiotherapy (RT) associated with chemotherapy (CT) according to the initial data (T3/T4 or N+). After first surgery, RT is indicated (except T1N0 with complete resection) associated with a CT based on postoperative data (capsular effraction or incomplete resection). Lymph node irradiation is considered case by case, but is indicated in any nodal involvement. RT must be an intensity modulated RT (IMRT), static or dynamic, and must be imagery guided (IGRT). According to ICRU 83, doses to organs at risk and target volumes must be carried. Finally, after a post-treatment baseline imaging between 2 and 4 months, monitoring will be alternated with the ENT surgeon every 2 or 3 months for 2 years, then every 4 to 6 months for 5 years.
authors.affiliation: Département de radiothérapie, institut cancérologique de l'Ouest (ICO), site Paul-Papin, 15, rue André-Boquel, 49055 Angers cedex 02, France. Electronic address: guillaume.peyraga@hotmail.com.
authors.forename: G
authors.initials: G
authors.lastname: Peyraga
authors.affiliation: Département de radiothérapie, institut cancérologique de l'Ouest (ICO), site Paul-Papin, 15, rue André-Boquel, 49055 Angers cedex 02, France.
authors.forename: C
authors.initials: C
authors.lastname: Lafond
authors.affiliation: Département de radiothérapie, institut cancérologique de l'Ouest (ICO), site Paul-Papin, 15, rue André-Boquel, 49055 Angers cedex 02, France.
authors.forename: Y
authors.initials: Y
authors.lastname: Pointreau
authors.affiliation: Service de radiothérapie, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France.
authors.forename: P
authors.initials: P
authors.lastname: Giraud
authors.affiliation: Département de radiothérapie, centre Georges-François-Leclerc, 1, rue du Pr-Marion, 21000 Dijon, France.
authors.forename: P
authors.initials: P
authors.lastname: Maingon
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000532:radiotherapy* / Q000628:therapy; D000359:Aftercare; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000532:radiotherapy* / Q000628:therapy; D003131:Combined Modality Therapy; D019583:Dose Fractionation, Radiation; D006801:Humans; D015182:Lymphatic Irradiation; D008444:Maxillary Sinus Neoplasms / Q000532:radiotherapy; D009296:Nasal Cavity; D009669:Nose Neoplasms / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000532:radiotherapy* / Q000628:therapy; D058958:Organs at Risk; D010255:Paranasal Sinus Neoplasms / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000532:radiotherapy* / Q000628:therapy; D011832:Radiation Injuries / Q000209:etiology / Q000517:prevention & control; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted; D018714:Radiotherapy, Adjuvant / Q000379:methods / Q000592:standards; D061089:Radiotherapy, Image-Guided; D050397:Radiotherapy, Intensity-Modulated / Q000009:adverse effects / Q000379:methods* / Q000592:standards
keywords: Adenocarcinoma of the ethmoid sinus; Adénocarcinome de l’ethmoïde; Cancer nasosinusien; Carcinome épidermoïde des fosses nasales; Carcinome épidermoïde du sinus maxillaire; Paranasal sinus cancer; Paranasal sinus tumor; Radiation Therapy; Radiothérapie; Squamous cell carcinoma of the maxillary sinus; Squamous cell carcinoma of the nasal cavity; Tumeurs nasosinusiennes